TQB2102 for injection: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving TQB2102 for injection

• A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
  NCT07043725 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 78 locations
• A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
  NCT07003074 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 25 locations
• A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
  NCT06496490 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 25 locations
• The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
  NCT06452706 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 16 locations

Common questions

How many recruiting trials involve TQB2102 for injection?

4 recruiting trials across 4 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.